Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 189

1.

Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.

Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, Mâsse B, Eshleman SH, Hendrix C, Morrow K, Rooney JF, Soto-Torres L; HPTN 050 Protocol Team.

AIDS. 2006 Feb 28;20(4):543-51.

PMID:
16470118
[PubMed - indexed for MEDLINE]
2.

Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women.

El-Sadr WM, Mayer KH, Maslankowski L, Hoesley C, Justman J, Gai F, Mauck C, Absalon J, Morrow K, Mâsse B, Soto-Torres L, Kwiecien A.

AIDS. 2006 May 12;20(8):1109-16.

PMID:
16691061
[PubMed - indexed for MEDLINE]
3.

Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women.

Mayer KH, Karim SA, Kelly C, Maslankowski L, Rees H, Profy AT, Day J, Welch J, Rosenberg Z; HIV Prevention Trials Network (HPTN) 020 Protocol Team.

AIDS. 2003 Feb 14;17(3):321-9.

PMID:
12556685
[PubMed - indexed for MEDLINE]
4.

Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers.

Jespers VA, Van Roey JM, Beets GI, Buvé AM.

J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):154-8.

PMID:
17106275
[PubMed - indexed for MEDLINE]
5.

Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women.

Nel AM, Coplan P, van de Wijgert JH, Kapiga SH, von Mollendorf C, Geubbels E, Vyankandondera J, Rees HV, Masenga G, Kiwelu I, Moyes J, Smythe SC.

AIDS. 2009 Jul 31;23(12):1531-8. doi: 10.1097/QAD.0b013e32832c413d.

PMID:
19550287
[PubMed - indexed for MEDLINE]
6.

Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study.

Rosen RK, Morrow KM, Carballo-Diéguez A, Mantell JE, Hoffman S, Gai F, Maslankowski L, El-Sadr WM, Mayer KH.

J Womens Health (Larchmt). 2008 Apr;17(3):383-92. doi: 10.1089/jwh.2006.0325.

PMID:
18328009
[PubMed - indexed for MEDLINE]
7.

Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.

Elion R, Cohen C, Ward D, Ruane P, Ortiz R, Reddy YS, Ebrahimi R, McColl D, Kearney B, Fisher A, Flaherty J; BATON Study Group.

HIV Clin Trials. 2008 Jul-Aug;9(4):213-24. doi: 10.1310/hct0904-213.

PMID:
18753116
[PubMed - indexed for MEDLINE]
8.

Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study.

O'Loughlin J, Millwood IY, McDonald HM, Price CF, Kaldor JM, Paull JR.

Sex Transm Dis. 2010 Feb;37(2):100-4. doi: 10.1097/OLQ.0b013e3181bc0aac.

PMID:
19823111
[PubMed - indexed for MEDLINE]
9.

Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons.

Young B, Weidle PJ, Baker RK, Armon C, Wood KC, Moorman AC, Holmberg SD; HIV Outpatient Study (HOPS) Investigators.

AIDS Patient Care STDS. 2006 Apr;20(4):238-44.

PMID:
16623622
[PubMed - indexed for MEDLINE]
10.

Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.

Dominguez S, Ghosn J, Peytavin G, Izzedine H, Wirden M, Ktorza N, Miller M, Aubron-Olivier C, Trylesinski A, Calvez V, Deray G, Katlama C.

J Med Virol. 2007 Feb;79(2):105-10.

PMID:
17177308
[PubMed - indexed for MEDLINE]
11.

Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.

TEmAA ANRS 12109 Study group, Arrivé E, Chaix ML, Nerrienet E, Blanche S, Rouzioux C, Coffie PA, Kruy Leang S, McIntyre J, Avit D, Srey VH, Gray G, N'Dri-Yoman T, Diallo A, Ekouévi DK, Dabis F.

AIDS. 2009 Apr 27;23(7):825-33. doi: 10.1097/QAD.0b013e32832949d5.

PMID:
19307941
[PubMed - indexed for MEDLINE]
12.

A randomized, double-blind, placebo-controlled Phase II extended safety study of two Invisible Condom formulations in Cameroonian women.

Mbopi-Keou FX, Trottier S, Omar RF, Nkele NN, Fokoua S, Mbu ER, Domingo MC, Giguère JF, Piret J, Mwatha A, Mâsse B, Bergeron MG.

Contraception. 2010 Jan;81(1):79-85. doi: 10.1016/j.contraception.2009.07.002. Epub .

PMID:
20004278
[PubMed - indexed for MEDLINE]
13.

A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women.

Van Damme L, Wright A, Depraetere K, Rosenstein I, Vandersmissen V, Poulter L, McKinlay M, Van Dyck E, Weber J, Profy A, Laga M, Kitchen V.

Sex Transm Infect. 2000 Apr;76(2):126-30.

PMID:
10858715
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel.

Malonza IM, Mirembe F, Nakabiito C, Odusoga LO, Osinupebi OA, Hazari K, Chitlange S, Ali MM, Callahan M, Van Damme L.

AIDS. 2005 Dec 2;19(18):2157-63.

PMID:
16284466
[PubMed - indexed for MEDLINE]
15.

Adverse effects of tenofovir use in HIV-infected pregnant women and their infants.

Nurutdinova D, Onen NF, Hayes E, Mondy K, Overton ET.

Ann Pharmacother. 2008 Nov;42(11):1581-5. doi: 10.1345/aph.1L083. Epub 2008 Oct 28.

PMID:
18957630
[PubMed - indexed for MEDLINE]
16.

Carraguard Vaginal Gel Safety in HIV-Positive Women and Men in South Africa.

van de Wijgert JH, Braunstein SL, Morar NS, Jones HE, Madurai L, Strickfaden TT, Moodley M, Aboobaker J, Ndlovu G, Ferguson TM, Friedland BA, Hart CE, Ramjee G.

J Acquir Immune Defic Syndr. 2007 Dec 15;46(5):538-46.

PMID:
18193495
[PubMed - indexed for MEDLINE]
17.

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; CAPRISA 004 Trial Group.

Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19. Erratum in: Science. 2011 Jul 29;333(6042):524.

PMID:
20643915
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

A randomized controlled safety and acceptability trial of dextrin sulphate vaginal microbicide gel in sexually active women in Uganda.

Bakobaki JM, Lacey CJ, Bukenya MI, Nunn AJ, McCormack S, Byaruhanga RN, Okong P, Namukwaya SW, Grosskurth H, Whitworth JA.

AIDS. 2005 Dec 2;19(18):2149-56.

PMID:
16284465
[PubMed - indexed for MEDLINE]
19.

A randomized, double-blind, placebo-controlled safety and acceptability study of two Invisible Condom formulations in women from Cameroon.

Mbopi-Keou FX, Trottier S, Omar RF, Nkele NN, Fokoua S, Mbu ER, Giguere JF, Domingo MC, Piret J, Tsague L, Zekeng L, Mwatha A, Mâsse B, Bergeron MG.

Contraception. 2009 Nov;80(5):484-92. doi: 10.1016/j.contraception.2009.03.020. Epub 2009 May 23.

PMID:
19835725
[PubMed - indexed for MEDLINE]
20.

MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.

Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito C, Salata R, Soto-Torres L, Patterson K, Minnis AM, Gandham S, Gomez K, Richardson BA, Bumpus NN.

PLoS One. 2013;8(1):e55013. doi: 10.1371/journal.pone.0055013. Epub 2013 Jan 30.

PMID:
23383037
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk